Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases.

What To Know

This is a completed interventional clinical trial (NCT07380022) run by the University of Thessaly that tested two dietary supplements containing microbial phytase (Goodphyte IB Defense and Goodphyte Immunity) in adults with chronic diseases, including Crohn’s disease and ulcerative colitis. Each supplement was given as four capsules daily for two weeks.

The study’s primary aims were to assess acceptability and adherence; secondary aims included measuring changes in iron and zinc absorption and possible effects on quality of life. The trial enrolled up to 100 participants divided into two arms (50 per supplement).

Key inclusion criteria allowed adults with IBD in remission on stable medical therapy; people currently taking iron or zinc supplements, antibiotics, or other probiotic/prebiotic products were excluded.

Primary outcomes were questionnaire-based acceptability and self-reported adherence; biochemical testing of iron and zinc status was planned as a secondary outcome. This record describes study design, eligibility, interventions, and outcome measures but does not report efficacy results or safety findings.

If you’re interested in whether these supplements change iron or zinc levels or quality of life in IBD, look for a linked results posting on the trial record or a subsequent peer-reviewed publication.